Literature DB >> 23408598

A role for androgen reduction treatment in Kennedy disease?

Kenneth H Fischbeck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23408598      PMCID： PMC4283484          DOI： 10.1002/mus.23814

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  8 in total

Review 1.  Developing treatment for spinal and bulbar muscular atrophy.

Authors:  Kenneth H Fischbeck
Journal:  Prog Neurobiol       Date:  2012-06-02       Impact factor: 11.685

2.  An open trial of long-term testosterone suppression in spinal and bulbar muscular atrophy.

Authors:  Tomotaka Yamamoto; Kazuhiko Yokota; Rie Amao; Takashi Maeno; Nobuhiko Haga; Masataka Taguri; Hiroshi Ohtsu; Yaeko Ichikawa; Jun Goto; Shoji Tsuji
Journal:  Muscle Nerve       Date:  2013-03-20       Impact factor: 3.217

3.  Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy.

Authors:  Masahisa Katsuno; Hiroaki Adachi; Akito Kume; Mei Li; Yuji Nakagomi; Hisayoshi Niwa; Chen Sang; Yasushi Kobayashi; Manabu Doyu; Gen Sobue
Journal:  Neuron       Date:  2002-08-29       Impact factor: 17.173

4.  Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.

Authors:  Lindsay E Fernández-Rhodes; Angela D Kokkinis; Michelle J White; Charlotte A Watts; Sungyoung Auh; Neal O Jeffries; Joseph A Shrader; Tanya J Lehky; Li Li; Jennifer E Ryder; Ellen W Levy; Beth I Solomon; Michael O Harris-Love; Alison La Pean; Alice B Schindler; Cheunju Chen; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Lancet Neurol       Date:  2011-01-06       Impact factor: 44.182

5.  Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Yu Takeuchi; Motoshi Kawashima; Ichiro Yabe; Hidenao Sasaki; Masashi Aoki; Mitsuya Morita; Imaharu Nakano; Kazuaki Kanai; Shoichi Ito; Kinya Ishikawa; Hidehiro Mizusawa; Tomotaka Yamamoto; Shoji Tsuji; Kazuko Hasegawa; Takayoshi Shimohata; Masatoyo Nishizawa; Hiroaki Miyajima; Fumio Kanda; Yasuhiro Watanabe; Kenji Nakashima; Akira Tsujino; Taro Yamashita; Makoto Uchino; Yasushi Fujimoto; Fumiaki Tanaka; Gen Sobue
Journal:  Lancet Neurol       Date:  2010-08-04       Impact factor: 44.182

6.  Clinical features of spinal and bulbar muscular atrophy.

Authors:  Lindsay E Rhodes; Brandi K Freeman; Sungyoung Auh; Angela D Kokkinis; Alison La Pean; Cheunju Chen; Tanya J Lehky; Joseph A Shrader; Ellen W Levy; Michael Harris-Love; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Brain       Date:  2009-12       Impact factor: 13.501

7.  Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy.

Authors:  Erica S Chevalier-Larsen; Christopher J O'Brien; Huiyi Wang; Shannon C Jenkins; Latia Holder; Andrew P Lieberman; Diane E Merry
Journal:  J Neurosci       Date:  2004-05-19       Impact factor: 6.167

8.  Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.

Authors:  Haruhiko Banno; Masahisa Katsuno; Keisuke Suzuki; Yu Takeuchi; Motoshi Kawashima; Noriaki Suga; Motoko Takamori; Mizuki Ito; Tomohiko Nakamura; Koji Matsuo; Shinichi Yamada; Yumiko Oki; Hiroaki Adachi; Makoto Minamiyama; Masahiro Waza; Naoki Atsuta; Hirohisa Watanabe; Yasushi Fujimoto; Tsutomu Nakashima; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422
  8 in total
  2 in total

Review 1.  Spinal and Bulbar Muscular Atrophy Overview.

Authors:  Kenneth H Fischbeck
Journal:  J Mol Neurosci       Date:  2015-11-07       Impact factor: 3.444

2.  The challenges of androgen insensitivity syndrome.

Authors:  Bratu Ovidiu; Dragos R Marcu; Dan L D Mischianu; Catalina Poiana; Camelia C Diaconu; Simona G Bungau; Delia M Tit; Alin Cumpanas; Roxana Bohiltea
Journal:  Arch Med Sci       Date:  2021-03-15       Impact factor: 3.707
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.